Drug intelligence / Profile preview

PCAR-019

Development stage: Phase 2
Lead developer: PersonGen BioTherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PCAR-019 is an autologous anti-CD19 chimeric antigen receptor (CAR)-T cell therapy developed by PersonGen BioTherapeutics. It is designed to treat various CD19-positive B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), follicular lymphoma, mantle cell lymphoma, B-cell prolymphocytic leukemia, and diffuse large B-cell lymphoma. The therapy involves engineering a patient's own T cells to express a CAR that targets the CD19 antigen on malignant B cells. Upon administration, these modified T cells specifically recognize and kill CD19-expressing tumor cells[1][2][3][5]. The drug is currently in phase 2 clinical trials for multiple indications.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on PCAR-019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCAR-019.

Explore the full profile